Journal article
Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on‐treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)‐2 Trial
Abstract
High on-treatment platelet reactivity (HOPR) is associated with increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI). We randomised post-PCI patients with HOPR after 5 days of standard dual antiplatelet therapy (DAPT) to intensified therapy with aspirin 100 mg once daily in combination with either clopidogrel 150 mg once daily, clopidogrel 75 mg once daily plus cilostazol 100 mg twice daily, …
Authors
Ying L; Wang J; Li J; Teng J; Zhang X; Ullah I; Samee A; Xu K; Chen J; Xu L
Journal
British Journal of Haematology, Vol. 196, No. 2, pp. 424–432
Publisher
Wiley
Publication Date
January 2022
DOI
10.1111/bjh.17847
ISSN
0007-1048